File this under “Who’da thunk it?”
In a surprising development, Merck reported that a cholesterol-lowering drug met its primary goals in a trial that was measuring cardiovascular outcomes. The reason this comes as a surprise is that the type of medicine being studied has repeatedly failed when other drug makers pursued their own versions.
About the Author Reprints
